Thromb Haemost 2005; 94(04): 867-871
DOI: 10.1160/TH04-03-0189
Cellular Proteolysis and Oncology
Schattauer GmbH

Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients

The MC-4 cancer substudy
Ajay K. Kakkar
1   Centre for Surgical Sciences, St. Bartholomew’s and The London Hospitals Medical School, London, UK
,
Sylvia Haas
2   Institut für Experimentelle Onkologie und Therapieforschung, Technical University of Munich, Germany
,
Helmut Wolf
3   Novartis Pharma GmbH, Nürnberg, Germany
,
Albrecht Encke
4   Zentrum für Chirurgie, University of Frankfurt/Main, Germany
› Author Affiliations
Grant support:This study was supported by a grant from Novartis Pharma GmbH, Nürnberg, Germany
Further Information

Publication History

Received22 October 2002

Accepted after revision14 July 2005

Publication Date:
07 December 2017 (online)

Zoom Image

Summary

Cancer patients undergoing surgery are at a high risk of venous thromboembolism, but few studies have described the rate of autopsy-confirmed fatal pulmonary embolism after heparin thromboprophylaxis. In a post hoc analysis of a randomized study (MC-4), which compared the efficacy and safety of certoparin (3000 anti-Xa IU, subcutaneously, once-daily) with unfractionated heparin (5000 IU, subcutaneously, three-times daily) in 23078 patients undergoing surgery lasting more than 30 min, the incidence of autopsy-confirmed fatal pulmonary embolism, death and bleeding in the cancer patients (n=6124) was compared with non-cancer patients (n=16954). Fatal pulmonary embolism was significantly more frequent in cancer patients (0.33% [20/6124]) than in non-cancer patients (0.09% [15/16954], relative risk (RR), 3.7 [95% confidence intervals (CI), 1.80, 7.77], p=0.0001) at 14 days post-prophylaxis. Perioperative mortality was also significantly higher in cancer patients than in noncancer patients (3.14% [192/6124] vs. 0.71% [120/16954], RR, 4.54 [95% CI, 3.59, 5.76], p=0.0001), as were blood loss (p<0.0001), and transfusion requirements (p<0.0001). Prevention of venous thromboembolism in cancer surgical patients remains a clinical challenge.